The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-31

Study Completion Date

2020-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Teduglutide in Short Bowel Syndrome Patients

NCT04857801

Short Bowel Syndrome

COMPLETED

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254

Gastroparesis GERD Esophagitis +4 more

TERMINATED NA

Domperidone in Refractory Gastroparesis

NCT00760461

Gastroparesis

TERMINATED PHASE2

Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency

NCT01696656

Intestinal Insufficiency Short Bowel Syndrome

COMPLETED

Lanreotide in the Treatment of Small Bowel Motility Disorders

NCT03012594

Gastrointestinal Motility Disorder Intestinal Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The only effective (to some extend drug) in short bowel syndrome is Glucacone-like peptide 4. Its price is, however, to high to really change the treatment strategy for intestinal failure. The Dipeptidyl peptidase-4 inhibitor, which a drug which is commonly used in the treatment of diabetes mellitus type II, should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Short Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DPP-4

The administration of the DPP-4 inhibitor in the form of a pill once per day

Group Type EXPERIMENTAL

Dipeptidyl peptidase-4 inhibitor

Intervention Type DRUG

NO DPP

no therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dipeptidyl peptidase-4 inhibitor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sitagliptin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months
* stable metabolic status
* benign disease